Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
57.55 x 2 68.00 x 1
Post-market by (Cboe BZX)
59.84 +0.61 (+1.03%) 04/23/25 [NASDAQ]
57.55 x 2 68.00 x 1
Post-market 59.84 unch (unch) 17:42 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
59.03
Day High
61.78
Open 60.61
Previous Close 59.23 59.23
Volume 782,170 782,170
Avg Vol 961,133 961,133
Stochastic %K 81.06% 81.06%
Weighted Alpha +21.73 +21.73
5-Day Change -2.25 (-3.62%) -2.25 (-3.62%)
52-Week Range 35.17 - 68.58 35.17 - 68.58
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,744,757
  • Shares Outstanding, K 63,224
  • Annual Sales, $ 130,130 K
  • Annual Income, $ -260,600 K
  • EBIT $ -266 M
  • EBITDA $ -264 M
  • 60-Month Beta 2.32
  • Price/Sales 29.39
  • Price/Cash Flow N/A
  • Price/Book 171.06

Options Overview Details

View History
  • Implied Volatility 52.62% ( +4.80%)
  • Historical Volatility 67.10%
  • IV Percentile 52%
  • IV Rank 23.79%
  • IV High 95.10% on 04/04/25
  • IV Low 39.36% on 11/19/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 76
  • Volume Avg (30-Day) 491
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 5,371
  • Open Int (30-Day) 6,094

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.69
  • Number of Estimates 12
  • High Estimate -0.51
  • Low Estimate -0.80
  • Prior Year -2.35
  • Growth Rate Est. (year over year) +70.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.90 +30.37%
on 04/07/25
Period Open: 52.04
63.11 -5.18%
on 04/08/25
+7.80 (+14.99%)
since 03/21/25
3-Month
45.90 +30.37%
on 04/07/25
Period Open: 58.47
63.11 -5.18%
on 04/08/25
+1.37 (+2.34%)
since 01/23/25
52-Week
35.17 +70.15%
on 05/29/24
Period Open: 40.00
68.58 -12.74%
on 11/11/24
+19.84 (+49.60%)
since 04/23/24

Most Recent Stories

More News
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

RYTM : 59.84 (+1.03%)
5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008

The tech-heavy Nasdaq Composite Index saw the largest intraday swing since 2008 in the April 8 trading session. The index closed 0.1% higher yesterday after swinging from a loss of around 5.2% to a gain...

SMCI : 32.90 (+7.59%)
RYTM : 59.84 (+1.03%)
GTX : 9.35 (+3.77%)
GOGL : 7.65 (+8.66%)
RGTI : 9.11 (+6.30%)
ONEQ : 65.62 (+2.32%)
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.

RYTM : 59.84 (+1.03%)
VTI : 263.44 (+1.70%)
IWM : 190.25 (+1.48%)
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

RYTM : 59.84 (+1.03%)
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

RYTM : 59.84 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 64.15
2nd Resistance Point 62.97
1st Resistance Point 61.40
Last Price 59.84
1st Support Level 58.65
2nd Support Level 57.47
3rd Support Level 55.90

See More

52-Week High 68.58
Last Price 59.84
Fibonacci 61.8% 55.82
Fibonacci 50% 51.88
Fibonacci 38.2% 47.93
52-Week Low 35.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective